A 58-year-old man with metastatic gastric cancer is receiving palliative chemotherapy and complains of persistent nausea, retching, and loss of appetite. He has no mechanical obstruction, and his renal function is normal (eGFR 65 mL/min). Previous trials of ondansetron and metoclopramide provided minimal relief. His oncologist suspects opioid-induced nausea (he is on morphine 60 mg/day for pain). Which antiemetic agent is most appropriate given his clinical context and renal function?

Explanation

## Opioid-Induced Nausea and Vomiting (OINV) in Palliative Care ### Pathophysiology of OINV Opioids induce nausea via multiple mechanisms: 1. **Direct chemoreceptor trigger zone activation** (μ-receptor agonism) 2. **Vestibular sensitivity** (increased motion perception) 3. **Delayed gastric emptying** (μ-receptor effects on antral smooth muscle) 4. **Increased intracranial pressure** (in susceptible patients) **Key Point:** OINV is **NOT mediated by serotonin release** — therefore, 5-HT3 antagonists (ondansetron, granisetron) are often ineffective as monotherapy. ### Antiemetic Efficacy in OINV | Agent | Mechanism | Efficacy in OINV | Notes | |---|---|---|---| | **Haloperidol** | D2 antagonist (dopamine blockade in CTZ) | **Excellent** | First-line for OINV; crosses BBB; low cost | | **Cyclizine** | H1 + muscarinic antagonist | Moderate | Better for vestibular component; sedating | | **5-HT3 antagonists** (ondansetron, granisetron) | Serotonin blockade | **Poor** | Ineffective for pure OINV; patient already failed ondansetron | | **Prochlorperazine** | D2 antagonist + H1 antagonism | Moderate | Extrapyramidal risk; less effective than haloperidol | | **Metoclopramide** | D2 antagonist + weak 5-HT4 agonist | Moderate | Tardive dyskinesia risk; patient already failed | **High-Yield:** **Haloperidol is the gold-standard antiemetic for opioid-induced nausea** in palliative care settings. It is superior to 5-HT3 antagonists because it directly blocks dopamine in the chemoreceptor trigger zone — the primary pathway for OINV. ### Why Haloperidol Is Correct - **Mechanism:** Potent D2 antagonist; crosses blood–brain barrier; blocks dopamine in chemoreceptor trigger zone and vomiting centre - **Efficacy in OINV:** Superior to ondansetron and metoclopramide for opioid-induced emesis - **Renal function:** Minimal renal excretion; safe in eGFR 65 mL/min (no dose adjustment needed) - **Dosing:** 1–2 mg once or twice daily; can be escalated to 5–10 mg/day if needed - **Palliative context:** Excellent tolerability; anxiolytic properties beneficial in end-of-life care **Clinical Pearl:** Haloperidol can be given IV, IM, or oral in palliative settings. It has a long half-life (~24 hrs) and can be dosed once daily for convenience. ### Why Other Options Fail **Granisetron (5-HT3 antagonist):** - Patient already failed ondansetron (another 5-HT3 antagonist) - 5-HT3 antagonists are ineffective for pure OINV because opioid-induced nausea is **NOT serotonin-mediated** - Cross-class resistance: failure of one 5-HT3 antagonist predicts failure of another **Cyclizine (H1 + muscarinic antagonist):** - Effective for vestibular nausea and motion sickness, not primary OINV - Anticholinergic side effects (dry mouth, urinary retention, confusion) problematic in elderly palliative patients - Less potent than haloperidol for chemoreceptor trigger zone blockade **Prochlorperazine (D2 antagonist + H1 antagonism):** - Weaker D2 antagonism than haloperidol - Higher risk of extrapyramidal side effects (dystonia, akathisia, parkinsonism) — particularly concerning in elderly - Less effective than haloperidol for OINV in clinical practice ## Antiemetic Selection Algorithm for Opioid-Induced Nausea ```mermaid flowchart TD A[Opioid-induced nausea]:::outcome --> B{Mechanism?}:::decision B -->|Chemoreceptor trigger zone| C[Haloperidol 1-2 mg daily]:::action B -->|Vestibular/motion component| D[Cyclizine 50 mg TDS]:::action B -->|Mixed| E[Haloperidol + Cyclizine]:::action C --> F{Response?}:::decision F -->|Yes| G[Continue; monitor QTc]:::action F -->|No| H[Increase to 5-10 mg/day or add second agent]:::action ``` **Mnemonic:** **HALO** = **H**aloperidol = **A**ntiemetic of choice for **L**ow-dose **O**pioid nausea. ### Safety Considerations - **QTc prolongation:** Haloperidol can prolong QT interval at high doses (>10 mg/day); baseline ECG recommended in elderly - **Renal function:** This patient's eGFR 65 is adequate; no dose adjustment needed - **Drug interactions:** Minimal with opioids; monitor with other QT-prolonging drugs - **Extrapyramidal effects:** Rare at low doses (1–2 mg/day); more common at higher doses